SAN FRANCISCO, CA--(Marketwired - February 14, 2017) - Cantabio Pharmaceuticals Inc. CTBO, a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that Dr. Gergely Toth, Cantabio's CEO, will present results of the company's Tau protein targeting small molecule pharmacological chaperone therapeutic program at the 13^th International Conference on Alzheimer's and Parkinson's Disease held in Vienna between March 29 - April 2.

Aggregation of the Tau protein is linked to the onset and progression of Alzheimer's disease (AD) and other Tauopathies, a subset of neurodegenerative disorders, including AD and frontotemporal dementias. Tau is one of the most recognized targets for the potential treatment of AD.

The presentations will describe the positive biological activity in cellular and in vivo models of AD of Cantabio's novel Tau protein targeting small molecule drug candidates including:

• Significant alleviation of movement deficit in a genetically modified, human Tau over-expressing fly in its motor neurons, an in vivo disease AD model and
• Significant reduction of the formation of Tau aggregates in vitro and in Tau over-expressing N2a neublastoma cells.

The data will be presented on:

March 29, 8:00-18:00 CET -- B03.e. Drug Development, Clinical Trials: Aggregation inhibitor; Abstract Number 214
The poster titled, "Novel tau aggregation inhibitor alleviates movement deficits in a fly model of tauopathy"

March 29, 8:00-18:00 CET -- B03.e. Drug Development, Clinical Trials: Aggregation inhibitor; Abstract Number 215
The poster titled, "Tau fibril binding novel small molecule inhibits aggregation of tau in vitro and in N2a cell model"

March 29, 8:00-18:00 CET -- B02.a. Therapeutic Targets, Mechanisms for Treatment: Tau, phosphorylation, truncation; Abstract Number 200
The poster titled, "Identification and characterization of small molecule binding sites of monomeric tau conformational ensembles"

The presentations are co-authored by researchers from the University of Cambridge, (UK), CAESAR Research Center, MPG, (Germany) and the Hungarian Academy of Sciences (Hungary).

Cantabio's CEO, Gergely Toth said: "We are delighted to share our exciting results for the first time on our Tau protein targeting pharmacological chaperone program. The presented results from our in-house and collaborators' work in cellular and in vivo models of Taupathies highlight the great potential of our candidates as a disease modifying therapeutic for Alzheimer's disease, and further validates our approach of tackling the disease at its source by preventing the formation of the toxic aggregates that are considered a root cause of the disease."

About Cantabio

Cantabio is focused on bringing novel, first in class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer's and Parkinson's, and oxidative stress. More information is available at www.cantabio.com.

Forward-Looking Statements:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.